Opthea Ltd ADR (OPT) Stock Price, Quote & News

Company Profile

Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian T...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9826 0399

Fax: 61 3 9824 0083

Website: opthea.com

Address:

Level 9, 505 Little Collins Street, Melbourne, Australia

goldrush77 Mar. 3 at 3:22 PM

$OPT 1,000,000 @bid . That is 0.7 % of the total shares

0 · Reply

goldrush77 Mar. 2 at 5:47 PM

$OPT Not a Pinkshit : "As at 31 December 2025....The Company held cash and cash equivalents of $33.2 million."

1 · Reply

goldrush77 Mar. 2 at 5:36 PM

$OPT Reports '25 audited. Relisting ASX on the way...

0 · Reply

goldrush77 Mar. 2 at 5:26 PM

$OPT This is a big one: Net tangible assets per ADR (=8 shares) =0.14 USD new !!! (previous period -1.42USD (correct read: minus!) https://ir.opthea.com/static-files/a874747e-3b6e-4016-882c-471a882eb1b1

0 · Reply

Nhraracer Jan. 13 at 12:31 AM

$OPTT this is $OPT dummy not $OPTT 2 different tickers but nice try pumper😂🤣

5 · Reply

TwongStocks Nov. 20 at 1:45 AM

$OPT FINRA's daily list confirms this will trade OTC effective Nov 20. New symbol is $OPTEY https://otce.finra.org/otce/dailyList

0 · Reply

OPTIOBlockchain Nov. 16 at 7:56 PM

$INJ.X Good add here! Check out $OPT it is listing at 8:00 am on MEXC

0 · Reply

OPTIOBlockchain Nov. 5 at 2:25 PM

$BETA.X Check out news for $OPT

0 · Reply

hagentrader Nov. 5 at 1:05 AM

$OPT Training = revenue with very low expense $$$$

0 · Reply

geegor Oct. 29 at 10:44 PM

$OPT seeks delisting from Nasdaq, with last trading expected here on or about Nov 19:

1 · Reply

Opthea Quarterly report: H1 2026

Nov 10, 2025, 5:00 PM EST - 7 months ago

Opthea Transcript: AGM 2025

Oct 29, 2025, 7:00 PM EDT - 7 months ago

Opthea Earnings release: Q1 2026

Aug 29, 2025, 3:30 AM EDT - 10 months ago

Opthea Annual report: H2 2025

Aug 29, 2025, 3:30 AM EDT - 10 months ago

Opthea Annual report: H2 2025

Aug 29, 2025, 3:30 AM EDT - 10 months ago

Opthea Earnings release: H2 2025

Aug 19, 2025, 7:00 PM EDT - 10 months ago

Opthea Transcript: Investor Update

Aug 19, 2025, 7:00 PM EDT - 10 months ago

Opthea Press release: Investor Update

Aug 19, 2025, 7:00 PM EDT - 10 months ago

Opthea Slides: Investor Update

Aug 18, 2025, 7:00 PM EDT - 10 months ago

Opthea Provides Corporate Update

Jul 29, 2025, 6:00 PM EDT - 11 months ago

Opthea Earnings release: Q4 2025

Mar 31, 2025, 12:01 AM EDT - 1 year ago

Opthea Announces Decision to Discontinue Wet AMD Trials

Mar 24, 2025, 12:01 AM EDT - 1 year ago

Opthea Announces COAST Phase 3 Trial Topline Results

Mar 23, 2025, 7:00 PM EDT - 1 year ago

Opthea Press release: Study Result

Mar 3, 2025, 7:00 AM EST - 1 year ago

Opthea Announces Phase 2b Wet AMD Publication

Feb 27, 2025, 6:00 PM EST - 1 year ago

Opthea Quarterly report: H1 2025

Feb 11, 2025, 10:00 AM EST - 1 year ago

Opthea Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 7, 2025, 7:00 AM EST - 1 year ago

Opthea to Present at Oppenheimer Healthcare Conference

Feb 6, 2025, 7:00 AM EST - 1 year ago

Opthea Wet AMD Data Featured at Macula Society Meeting

Jan 28, 2025, 1:30 PM EST - 1 year ago

Opthea Transcript: Investor Day 2025

Jan 28, 2025, 1:30 PM EST - 1 year ago

Opthea Slides: FY 2025

Jan 15, 2025, 8:15 PM EST - 1 year ago

Opthea Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 12, 2025, 9:00 PM EST - 1 year ago

Opthea Slides: Investor Presentation

Jan 8, 2025, 7:00 AM EST - 1 year ago

Opthea to Host Investor Days in New York and Australia

Dec 19, 2024, 7:00 AM EST - 1 year ago

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 5, 2024, 1:45 PM EST - 1 year ago

Opthea Transcript: Citi's 2024 Global Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Opthea's Wet AMD Program to be Featured at FLORetina 2024

Nov 18, 2024, 9:00 PM EST - 1 year ago

Opthea Slides: Investor Presentation

Nov 15, 2024, 7:00 AM EST - 1 year ago

Opthea Appoints Kathy Connell to Board of Directors

Oct 27, 2024, 9:00 PM EDT - 1 year ago

Opthea Slides: Investor Presentation

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Opthea Wet AMD Program to be Presented at Innovate Retina

Oct 2, 2024, 4:00 PM EDT - 1 year ago

Opthea Transcript: UBS Virtual Ophthalmology Day Conference

Sep 30, 2024, 7:30 AM EDT - 1 year ago

Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

Sep 25, 2024, 10:00 PM EDT - 1 year ago

Opthea Slides: Investor Presentation

Sep 18, 2024, 7:30 AM EDT - 1 year ago

Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept

Sep 17, 2024, 8:35 AM EDT - 1 year ago

Opthea Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Opthea Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 6:00 AM EDT - 1 year ago

Opthea Announces Executive Leadership Changes and Senior Hires

Sep 3, 2024, 8:00 PM EDT - 1 year ago

Opthea Slides: Investor Presentation

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference

Aug 30, 2024, 7:30 AM EDT - 1 year ago

Opthea Reports Full-Year Financial Results and Business Updates

Aug 30, 2024, 3:30 AM EDT - 1 year ago

Opthea Annual report: H2 2024

Aug 30, 2024, 3:30 AM EDT - 1 year ago

Opthea Annual report: H2 2024

Aug 30, 2024, 3:30 AM EDT - 1 year ago

Opthea Earnings release: H2 2024

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Opthea Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 8, 2024, 8:10 AM EDT - 1 year ago

Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024

Jul 17, 2024, 7:15 AM EDT - 2 years ago

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

Jul 14, 2024, 9:46 PM EDT - 2 years ago

Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer

Jun 18, 2024, 8:57 PM EDT - 2 years ago

Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens

Jun 13, 2024, 7:58 PM EDT - 2 years ago

Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)

Jun 11, 2024, 9:13 PM EDT - 2 years ago

Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)

Jun 6, 2024, 12:30 PM EDT - 2 years ago

Opthea Transcript: Jefferies 2024 Global Healthcare Conference

Jun 3, 2024, 7:30 AM EDT - 2 years ago

Opthea To Present at Clinical Trials at the Summit Meeting

May 28, 2024, 7:30 AM EDT - 2 years ago

Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

May 1, 2024, 7:30 AM EDT - 2 years ago

Opthea Announces Upcoming Presentations at the Retina World Congress 2024

Apr 25, 2024, 9:00 AM EDT - 2 years ago

Opthea to Present at the OIS Retina Innovation Summit at ARVO

Apr 11, 2024, 3:45 PM EDT - 2 years ago

Opthea Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 8, 2024, 6:42 PM EDT - 2 years ago

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Apr 4, 2024, 6:34 PM EDT - 2 years ago

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 5:39 PM EDT - 2 years ago

Opthea Appoints Sujal Shah to the Board of Directors

Mar 19, 2024, 6:00 AM EDT - 2 years ago

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

Mar 5, 2024, 5:08 PM EST - 2 years ago

Opthea to Participate in the Leerink Partners Global Biopharma Conference

Feb 29, 2024, 2:00 AM EST - 2 years ago

Opthea Quarterly report: H1 2024

Feb 28, 2024, 5:55 PM EST - 2 years ago

Opthea Reports Half-Year Financial Results and Business Updates

Feb 19, 2024, 6:25 PM EST - 2 years ago

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

Feb 14, 2024, 7:00 AM EST - 2 years ago

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

Feb 1, 2024, 6:00 AM EST - 2 years ago

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Dec 27, 2023, 6:00 AM EST - 2 years ago

Opthea to Receive US$35M Commitment and Additional US$50M Funding

Dec 19, 2023, 6:00 AM EST - 2 years ago

Opthea Receives A$8.8 million R&D Tax Incentive

Dec 1, 2023, 5:30 AM EST - 2 years ago

Opthea to Present at the FLORetina 2023 Congress

Nov 15, 2023, 7:20 AM EST - 2 years ago

Opthea Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Nov 9, 2023, 5:30 AM EST - 2 years ago

Opthea to Present at the Jefferies 2023 London Healthcare Conference

Oct 30, 2023, 5:30 AM EDT - 2 years ago

Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference

Oct 27, 2023, 5:30 AM EDT - 2 years ago

Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO

Oct 2, 2023, 5:30 AM EDT - 2 years ago

Opthea to Participate at the 2023 Euretina Congress

Sep 7, 2023, 5:30 AM EDT - 2 years ago

Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 1, 2023, 12:00 PM EDT - 3 years ago

Opthea Slides: Corporate Presentation

Aug 29, 2023, 8:00 PM EDT - 3 years ago

Opthea Annual report: H2 2023

Aug 29, 2023, 8:00 PM EDT - 3 years ago

Opthea Annual report: H2 2023

Aug 29, 2023, 8:00 PM EDT - 3 years ago

Opthea Earnings release: H2 2023

Aug 28, 2023, 5:30 AM EDT - 3 years ago

Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)

Jul 26, 2023, 6:00 AM EDT - 3 years ago

Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Jul 24, 2023, 6:00 AM EDT - 3 years ago

Opthea to Present at the 2023 Ophthalmology Innovation Summit

Jul 13, 2023, 6:00 AM EDT - 3 years ago

Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting

Jul 10, 2023, 6:00 AM EDT - 3 years ago

Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor

Jun 8, 2023, 6:00 AM EDT - 3 years ago

Opthea Appoints Anshul Thakral as Non-Executive Director of the Board

goldrush77 Mar. 3 at 3:22 PM

$OPT 1,000,000 @bid . That is 0.7 % of the total shares

0 · Reply

goldrush77 Mar. 2 at 5:47 PM

$OPT Not a Pinkshit : "As at 31 December 2025....The Company held cash and cash equivalents of $33.2 million."

1 · Reply

goldrush77 Mar. 2 at 5:36 PM

$OPT Reports '25 audited. Relisting ASX on the way...

0 · Reply

goldrush77 Mar. 2 at 5:26 PM

0 · Reply

Nhraracer Jan. 13 at 12:31 AM

$OPTT this is $OPT dummy not $OPTT 2 different tickers but nice try pumper😂🤣

5 · Reply

TwongStocks Nov. 20 at 1:45 AM

$OPT FINRA's daily list confirms this will trade OTC effective Nov 20. New symbol is $OPTEY https://otce.finra.org/otce/dailyList

0 · Reply

OPTIOBlockchain Nov. 16 at 7:56 PM

$INJ.X Good add here! Check out $OPT it is listing at 8:00 am on MEXC

0 · Reply

OPTIOBlockchain Nov. 5 at 2:25 PM

$BETA.X Check out news for $OPT

0 · Reply

hagentrader Nov. 5 at 1:05 AM

$OPT Training = revenue with very low expense $$$$

0 · Reply

geegor Oct. 29 at 10:44 PM

$OPT seeks delisting from Nasdaq, with last trading expected here on or about Nov 19:

1 · Reply

OPTIOBlockchain Oct. 29 at 12:02 AM

$OPT.X Parler Cloud Technologies was just mentioned in SEC Filings yesterday with AMZE. Parler Cloud Technologies will be going the NYSE via IPO late Q1 or early Q2 2026 and is was valued at over 1.5 Billion a few months ago. A very very bright future for $OPT

0 · Reply

TwongStocks Aug. 20 at 2:05 PM

$OPT Link to corporate presentation of the latest status https://www.sec.gov/Archives/edgar/data/1815620/000095017025110268/opt-ex99_1.htm • After negative topline of COAST & ShORE trials, OPT decided to terminate Sozinibercept wet AMD program after consultation with DFA investors. • OPT settled with DFA investors, with a cash payment of $20M USD and 9.99% equity stake (136.7m shares). The DFA and all liens are terminated. • After settlement, OPT has $20M cash and ~1.4B shares outstanding. No more debt, no liens on any asset. • Trading remains suspended on ASX and NASDAQ. OPT engaging with ASX, I assume NASDAQ will resume trading once trading resumes on ASX. • Remaining board members will pursue strategic transactions

0 · Reply

TwongStocks Aug. 18 at 11:13 PM

$OPT They have finally issued an update https://opthealimited.gcs-web.com/news-releases/news-release-details/opthea-provides-corporate-update-2 • CEO, CFO, and one of the Directors are stepping down. • Board of Directors will conduct a strategic review • They have come to an agreement with the DFA investors. As part of the settlement, the DFA investors will be issued 9.99% of company shares. They will also receive a one-time cash payout of $20M USD. • Trading in ASX remains suspended. I assume NASDAQ will also maintain a halt while trading is suspended on the ASX. • The Company will host a webcast on Tuesday 19 August at 7pm ET/Wednesday 20 August at 9am AEDT.

0 · Reply

tommytoughknuckles Jun. 27 at 2:19 AM

$OPT how long can they keep this halted for??

1 · Reply

liquidmetal Jun. 22 at 5:23 PM

$OPT, ethernet at sea. Equip to handle 5g and beyond antena. https://oceanpowertechnologies.com/products/powerbuoys/

0 · Reply

PaytiencePaysGreen Jun. 18 at 11:30 AM

$BTAI POS stock. Prob gonna add to the family and be the same as $SYRS $PTN $OPT . Check these twits out at their board

0 · Reply

geegor Jun. 2 at 9:41 AM

$OPT Four directors gone from the board today and "...Management plans to hold an investor call to discuss the Phase III trial results and next steps of the Company once active negotiations with the DFA investors have been concluded." https://www.marketindex.com.au/asx/opt/announcements/opthea-provides-corporate-update-3A669187

0 · Reply

TwongStocks Apr. 10 at 10:33 PM

$OPT Kind of wild. Trading will still remain paused, no timeline for resumption. "In light of these matters, there remains material uncertainty as to Opthea's ability to continue as a going concern. As noted above, discussions with the DFA Investors are ongoing and Opthea cannot be certain as to the outcome of those discussions or when that outcome may become known. " https://www.sec.gov/Archives/edgar/data/1815620/000095017025052661/opt-ex99_1.htm • 65% workforce reduction, expected to be effective May 1. • Remains in active negotiations with its DFA Investors to explore possible options to deliver the best outcome for the Company and its shareholders. • $100M at end of March

0 · Reply

briefingcom Apr. 10 at 12:48 PM

$OPT: Opthea Ltd. announces reduction in force of approximately 65% to preserve cash https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20250410063005OPT&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

tommytoughknuckles Apr. 8 at 5:03 AM

$OPT when the hell is this gonna start trading again?

0 · Reply

PaytiencePaysGreen Apr. 1 at 4:38 PM

$OPT outright daylight robbery to retailers. Opt to change name to Apt. Meet at the slaughterhouse...apt,apt,apt,apt..uh huh, uh huh

0 · Reply

Market Cap	524.84M
Revenue (ttm)	120,000.00
Net Income (ttm)	-220.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-183,533.34%
Debt to Equity Ratio	-1.32

Volume	3,000
Avg Vol	38,738
Day's Range	N/A - N/A
Shares Out	153.91M
Stochastic %K	33%
Beta	1.12
Analysts	Strong Sell
Price Target	$12.00